EUCTR2007-001389-34-GB进行中（未招募）不适用
A multi-centre, double-blind, placebo-controlled, multiple-dose crossover proof of concept study to compare the efficacy of mefenamic acid administered vaginally and orally in healthy menstruating women with primary dysmenorrhoea requiring analgesia. - PSD508-DYS-001
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 105
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •The study population will be normal healthy menstruating female volunteers. Subjects will have a self reported history of primary dysmenorrhoea that includes menstrual related pain with cramping for which they require analgesics.
- •Inclusion Criteria: A subject will be invited to participate if she meets the following inclusion criteria:
- •1. Is a healthy menstruating female with a history of primary dysmenorrhoea.
- •2. Has menstrual-related pain with cramping for which she requires the use of analgesics during each cycle.
- •3. Has regular menstrual cycles.
- •4. Routinely uses intra-vaginal tampons and is able to use tampons without an applicator.
- •5. Is aged 18 – 40 years inclusive.
- •6. Has no clinically significant medical history and normal clinical examination other than the underlying pathology requiring treatment, in the opinion of the Investigator.
- •7. Is able to understand and complete the rating scales.
- •8. Has provided written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Exclusion Criteria: A subject will be excluded from study participation if she meets any of the following criteria:
- •1. Has a history of, or known, hypersensitivity to mefenamic acid.
- •2. Has a history of reactions such as asthma, urticaria, or allergic type reactions to other non-steroidal anti-inflammatory drugs (NSAIDs).
- •3. Has received another investigational product within 3 months prior to screening.
- •4. Is unwilling to avoid the use of any 1) opiate within 24 hours, 2) NSAID within 6 hours, or 3) paracetamol within 4 hours, of starting study medication. [Up to 16 mg codeine per dose (i.e., 2 co-codamol 8/500 mg tablets) is allowed]
- •5. Is pregnant, lactating, or is planning to become pregnant during the study.
- •6. Is currently receiving or has received any hormonal contraception within the previous 3 months.
- •7. Does not agree to use suitable non-hormonal contraception for the duration of the study.
- •8. Has a history of toxic shock syndrome (TSS)
- •9. Has a current untreated STD that could interfere with the study.
- •10. Has, or has had, ulcerative, vesicular or papillomatous lesions of the cervix, vagina or genital area.
- •11. Is known not to respond to mefenamic acid.
- •12. Has signs or symptoms that contraindicate the administration of mefenamic acid.
- •13. Has unresolved alcohol or drug abuse.
- •14. Has severe menorrhagia which, in the opinion of the investigator, could interfere with the study.
- •15. Is using complementary therapy, such as evening primrose oil, for the treatment of symptoms.
- •16. Has any other condition which, in the opinion of the investigator, may interfere with the study.
研究者
相似试验
进行中（未招募）
不适用
A multi-centre, double-blind, placebo-controlled, randomised, parallel groupclinical trial to evaluate efficacy and safety of Actovegin® in diabetic type 2patients with symptomatic diabetic peripheral polyneuropathy - Actovegin® versus placebo in patients with diabetic polyneuropathyDiabetic PolyneuropathyMedDRA version: 8.1Level: LLTClassification code 10012685Term: Diabetic polyneuropathyEUCTR2006-004007-19-ATycomed Austria GmbH550
进行中（未招募）
不适用
A multi-centre, double-blind, placebo-controlled, randomised, parallel group study to assess the efficacy and safety of two different dosages of a herbal medicinal product (dry extract BNO-1016) in patients with acutre rhinosinusitisMulti-centre, double-blind, placebo-controlled, randomised, parallel group studyAcute rhinosinusitisMedDRA version: 9.1Level: LLTClassification code 10052106Term: RhinosinusitisEUCTR2008-002794-13-DEBionorica AG
进行中（未招募）
不适用
A multi-centre, double-blind, placebo-controlled, randomised, parallel group study to assess the efficacy and safety of a herbal medicinal product (dry extract BNO-1016) in patients with acute rhinosinusitis.Multi-centre, double-blind, placebo-controlled, randomised, parallel group studyAcute rhinosinusitisMedDRA version: 12.0Level: LLTClassification code 10052106Term: RhinosinusitisEUCTR2009-016682-28-DEBionorica AG
已完成
不适用
A multi-centre, double-blind, placebo-controlled, multiple-dose crossover proof of concept study to compare the efficacy of mefenamic acid administered vaginally and orally in healthy menstruating women with primary dysmenorrhoea requiring analgesiaPrimary dysmenorrhoeaUrological and Genital DiseasesDysmenorrhoeaISRCTN32847177Plethora Solutions Limited (UK)105
进行中（未招募）
不适用
Study to assess the safety and efficacy of KRP203 in active subacute cutaneous lupus erythematosus patients, who have shown poor response to standard treatment.Subacute cutaneous lupus erythematosus, in patients who do not respond to first line therapies (i.e. antimalrials)MedDRA version: 14.0Level: HLTClassification code 10025135Term: Lupus erythematosus (incl subtypes)System Organ Class: 10028395 - Musculoskeletal and connective tissue disordersEUCTR2010-019689-10-GRovartis Services AG24